Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 10/20 | 0.81 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418056 | 0.90 | CMA1 (1.00) | CMA1GPR84POLBKDM4E | |
| SCHEMBL7961042 | 0.90 | CMA1 (0.83) | CMA1POLB | |
| SCHEMBL7962647 | 0.82 | CMA1 (0.78) | CMA1POLBKDM4EALDH1A1LMNA | |
| SCHEMBL1851876 | 0.82 | CMA1 (0.83) | CMA1MAPT | |
| SCHEMBL7951286 | 0.79 | CMA1 (1.00) | CMA1POLB | |
| SCHEMBL7960524 | 0.79 | CMA1 (1.00) | CMA1GPR84POLBKDM4E | |
| SCHEMBL7961041 | 0.78 | CMA1 (0.80) | CMA1GPR84KDM4ELMNAMAPT | |
| SCHEMBL7951727 | 0.76 | CMA1 (1.00) | CMA1GPR84MAPT | |
| SCHEMBL18900835 | 0.76 | CMA1 (0.74) | CMA1GPR84POLBKDM4EHPGD | |
| SCHEMBL7959067 | 0.76 | CMA1 (0.85) | CMA1GPR84MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323991-B1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20120129863-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129863-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2010019417-A2 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129863-A1 | CHYMASE INHIBITORS | CMA1, CPA3, SERPINB1 | CMA1 1/4885GPR84 3124/4885POLB 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.